Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Long-lasting HIV prevention drug could be game changer — but who will pay?

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Nature 608, 460-461 (2022)


Updates & Corrections

  • Correction 16 August 2022: An earlier version of this article incorrectly stated the full name of Wits Reproductive Health and HIV Institute (Wits RHI).


  1. Delany-Moretlwe, S. et al. Lancet 339, 1779–1789 (2022).

    Article  Google Scholar 

  2. Jamieson, L. et al. Preprint at SSRN (2022).

Download references

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links